Trial record 1 of 1 for:    GLISTEN
Previous Study | Return to List | Next Study

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation (GLISTEN)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01610037
First received: May 30, 2012
Last updated: May 21, 2014
Last verified: May 2014
  Purpose

The study will assess the long-term safety of the fixed combination product QVA149 versus placebo and a standard of care treatment (tiotropium) in Chronic Obstructive Pulmonary Disease (COPD) patients with moderate to severe airflow limitation.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease (COPD)
Drug: QVA149
Drug: Tiotropium
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Placebo and Active Controlled Study to Assess the Long-term Safety of Once Daily QVA149 for 52 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients With Moderate to Severe Airflow Limitation

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • overall serious adverse event rate [ Time Frame: 56 weeks ] [ Designated as safety issue: Yes ]
    The overall rate of serious adverse events reported from initiation through 30 days post last dose will be analyzed.


Secondary Outcome Measures:
  • Composite endpoint of all-cause mortality and serious cerebro-cardiovascular events [ Time Frame: 56 weeks ] [ Designated as safety issue: Yes ]
    A composite endpoint of all-cause mortality and serious cerebro-cardiovascular events will be analyzed.

  • Electrocardiogram [ Time Frame: weeks 1, 26 and 52 ] [ Designated as safety issue: Yes ]
    Data from the electrocardiograms will be summarized by treatment at all times.

  • Health Status as measured by St. George's Respiratory Questionnaire for COPD patients (SGRQ-C) [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    The St. George's Respiratory Questionnaire (SGRQ-C) will be used to provide the health status measurement. The SGRQ-C contains 40 items divided into two parts covering three aspects of health related to Chronic Obstructive Pulmonary Disease. A score will be calculated for each of these three parts and a "Total" score will also be calculated. In each case the lowest possible value is zero and the highest 100. Higher values correspond to greater impairment of health status.

  • Daily, morning and evening symptom scores [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Patients will be provided with an electronic diary (eDiary) to record daily clinical symptoms, or rescue medication. The patients will be instructed to routinely complete the patient diary twice daily. There are 9 total symptom questions for a total possible score of 27 at each timepoint. A higher score means the patient is reporting more symptoms related to Chronic Obstructive Pulmonary Disease.

  • Percentage of nights with 'no nighttime awakenings' [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    A night with 'no nighttime awakenings' is defined from diary data as any night where the patient did not wake up due to symptoms. The percentage of nights with 'no nighttime awakenings' will be analyzed.

  • Percentage of days with 'no daytime symptoms' [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    A day with 'no daytime symptoms' is defined from the diary data as any day where the patient has recorded in the evening no cough, no wheeze, no production of sputum and no feeling of breathlessness (other than when running) during the past 12 hours (approx 8 am to 8 pm). The percentage of days with 'no daytime symptoms' will be analyzed.

  • Percentage of 'days able to perform usual daily activities' [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    A 'day able to perform usual daily activities' is defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms. The percentage of 'days able to perform usual daily activities' will be analyzed.

  • Pre-Dose forced expiratory volume over in second (FEV1) [ Time Frame: Weeks 3, 6, 12, 26, 39, and 52 ] [ Designated as safety issue: No ]
    The average pre-dose forced expiratory volume in 1 second (FEV1) at visit 4, 5, 6, 7, 8 and 9 will be analyzed.

  • Pre-Dose forced vital capacity (FVC) [ Time Frame: Weeks 3, 6, 12, 26, 39 and 52 ] [ Designated as safety issue: No ]
    The average pre-dose forced vital capacity (FVC) at visit 4, 5, 6, 7, 8 and 9 will be analyzed.

  • Post dose forced expiratory volume in one second (FEV1) [ Time Frame: Weeks 3, 6, 12, 26, 39, and 52 ] [ Designated as safety issue: No ]
    The avg 60 min post dose forced expiratory volume in 1 second (FEV1) at visit 4, 5, 6, 7, 8 and 9 will be analyzed.

  • Post Dose forced vital capacity (FVC) [ Time Frame: Weeks 3, 6, 12, 26, 39, and 52 ] [ Designated as safety issue: No ]
    The avg 60 min post dose forced vital capacity (FVC)at visit 4, 5, 6, 7, 8 and 9 will be analyzed.

  • Time to discontinuation [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
    Time to premature discontinuation will be displayed graphically for each treatment group.

  • Vital Signs [ Time Frame: Weeks 3, 6, 12, 26, 39, and 52 ] [ Designated as safety issue: Yes ]
    Vital signs (blood pressure and radial pulse rate) data will be summarized by treatment at pre-dose and 30 minute post-dose time points at Visits 3-9.

  • Lab values [ Time Frame: Weeks 6, 12, 26, 39, and 52 ] [ Designated as safety issue: Yes ]
    All lab data will be listed with abnormal values flagged. The lab values and the change from baseline for continuous lab parameters will be summarized at each visit. A frequency table of results for categorical lab parameters will be produced by visit. Shift tables relative to normal ranges will be used to summarize the change from baseline to post-baseline by visit.


Estimated Enrollment: 1224
Study Start Date: October 2012
Estimated Study Completion Date: January 2015
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: QVA149 Drug: QVA149
QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
Active Comparator: Tiotropium Drug: Tiotropium
Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
Placebo Comparator: placebo Drug: placebo
placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female adults aged ≥40 yrs
  • Smoking history of at least 10 pack years
  • Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) (moderate to severe airflow limitation as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2011)
  • Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)< 80% and ≥ 30% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) <70%
  • Modified Medical Research Council questionnaire grade of 2 or higher

Exclusion Criteria:

  • Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1
  • Patients with concomitant pulmonary disease
  • Patients with a history of asthma
  • Any patient with lung cancer or a history of lung cancer
  • Patients with a history of certain cardiovascular co-morbid conditions
  • Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency
  • Patients in the active phase of a supervised pulmonary rehabilitation program
  • Patients contraindicated for inhaled anticholinergic agents and β2 agonists
  • Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01610037

Contacts
Contact: Novartis Pharmaceuticals, 1862-778-8300 +41613241111
Contact: Novartis Pharmaceuticals

  Hide Study Locations
Locations
Argentina
Novartis Investigative Site Active, not recruiting
Caba, Buenos Aires, Argentina, C1122AAK
Novartis Investigative Site Withdrawn
Caba, Buenos Aires, Argentina, C1425BEA
Novartis Investigative Site Withdrawn
Caba, Buenos Aires, Argentina
Novartis Investigative Site Active, not recruiting
Caba, Buenos Aires, Argentina, C1425AUA
Novartis Investigative Site Active, not recruiting
Caba, Buenos Aires, Argentina, C1113AAC
Novartis Investigative Site Terminated
Caba, Buenos Aires, Argentina, C1180AAX
Novartis Investigative Site Active, not recruiting
Caba, Buenos Aires, Argentina, 1028
Novartis Investigative Site Active, not recruiting
Florida, Buenos Aires, Argentina, B1602DQD
Novartis Investigative Site Withdrawn
La Plata, Buenos Aires, Argentina, 1900
Novartis Investigative Site Active, not recruiting
Lanus, Buenos Aires, Argentina, B8000XAV
Novartis Investigative Site Active, not recruiting
Mar del Plata, Buenos Aires, Argentina, B7600FZN
Novartis Investigative Site Withdrawn
Mar del Plata, Buenos Aires, Argentina, B7602CBM
Novartis Investigative Site Active, not recruiting
Quilmes, Buenos Aires, Argentina, B1878FNR
Novartis Investigative Site Active, not recruiting
Rojas, Buenos Aires, Argentina, B2705XAE
Novartis Investigative Site Terminated
San Isidro, Buenos Aires, Argentina, B1642DCD
Novartis Investigative Site Active, not recruiting
Vicente Lopez, Buenos Aires, Argentina, B1638AAI
Novartis Investigative Site Withdrawn
Caba, Capital Federal, Argentina, C1425FVH
Novartis Investigative Site Active, not recruiting
Concepcion del Uruguay, Entre Rios, Argentina, E3260EPD
Novartis Investigative Site Active, not recruiting
Santa Fe, Rosario, Argentina, S2000DBS
Novartis Investigative Site Active, not recruiting
Rosario, Santa Fe, Argentina, S2000CXH
Novartis Investigative Site Active, not recruiting
Rosario, Santa Fe, Argentina, S2000AII
Novartis Investigative Site Active, not recruiting
San Miguel de Tucuman, Tucuman, Argentina, 4000
Novartis Investigative Site Active, not recruiting
Buenos Aires, Argentina, 1425
Novartis Investigative Site Active, not recruiting
Buenos Aires, Argentina, B1842DID
Novartis Investigative Site Withdrawn
Corrientes, Argentina, W3410AVV
Novartis Investigative Site Active, not recruiting
Corrientes, Argentina, W3400
Novartis Investigative Site Active, not recruiting
Mendoza, Argentina, 5500
Novartis Investigative Site Active, not recruiting
Mendoza, Argentina, M5500CBA
Novartis Investigative Site Active, not recruiting
Salta, Argentina, 4000
Novartis Investigative Site Active, not recruiting
Santa Fe, Argentina, S3000FIL
Novartis Investigative Site Active, not recruiting
Santa Fe, Argentina, S3000FWO
Colombia
Novartis Investigative Site Active, not recruiting
Bogota, Cundinamarca, Colombia
Novartis Investigative Site Active, not recruiting
Armenia, Colombia
Novartis Investigative Site Active, not recruiting
Barranquilla, Colombia
Novartis Investigative Site Withdrawn
Bogota, Colombia
Novartis Investigative Site Completed
Bogota, Colombia
Croatia
Novartis Investigative Site Active, not recruiting
Osijek, Croatia, 31000
Novartis Investigative Site Active, not recruiting
Sisak, Croatia, 44000
Novartis Investigative Site Withdrawn
Split, Croatia, 21000
Novartis Investigative Site Active, not recruiting
Zagreb, Croatia, 10 000
Novartis Investigative Site Active, not recruiting
Zagreb, Croatia, 10000
Dominican Republic
Novartis Investigative Site Withdrawn
Santo Domingo, Republica Dominicana, Dominican Republic
Estonia
Novartis Investigative Site Active, not recruiting
Tallinn, Estonia, 13619
Novartis Investigative Site Active, not recruiting
Tallinn, Estonia, 13419
Novartis Investigative Site Active, not recruiting
Tartu, Estonia, 51014
Guatemala
Novartis Investigative Site Withdrawn
Guatemala City, Guatemala, 01010
Hungary
Novartis Investigative Site Active, not recruiting
Budapest, Hungary, 1204
Novartis Investigative Site Active, not recruiting
Cegled, Hungary, 2700
Novartis Investigative Site Active, not recruiting
Csorna, Hungary, H-9300
Novartis Investigative Site Active, not recruiting
Debrecen, Hungary, 4032
Novartis Investigative Site Active, not recruiting
Eger, Hungary, 3300
Novartis Investigative Site Active, not recruiting
Erd, Hungary, H-2030
Novartis Investigative Site Active, not recruiting
Godollo, Hungary, 2100
Novartis Investigative Site Active, not recruiting
Monor, Hungary, 2200
Novartis Investigative Site Active, not recruiting
Mosonmagyarovar, Hungary, 9200
Novartis Investigative Site Active, not recruiting
Siofok, Hungary, 8600
Novartis Investigative Site Active, not recruiting
Szarvas, Hungary, 5540
India
Novartis Investigative Site Completed
Hyderabad, A.p., India, 500 001
Novartis Investigative Site Withdrawn
Hyderabad, Andhra Pradesh, India, 500012
Novartis Investigative Site Active, not recruiting
Hyderabad, Andhra Pradesh, India, 500004
Novartis Investigative Site Withdrawn
Bangalore, Karnataka, India, 560 068
Novartis Investigative Site Active, not recruiting
Bangalore, Karnataka, India, 560002
Novartis Investigative Site Withdrawn
Mangalore, Karnataka, India, 575001
Novartis Investigative Site Active, not recruiting
Mysore, Karnataka, India, 570004
Novartis Investigative Site Active, not recruiting
Trivandrum, Kerala, India, 695 011
Novartis Investigative Site Active, not recruiting
Nagpur, Maharashtra, India, 440033
Novartis Investigative Site Withdrawn
Pune, Maharashtra, India, 411014
Novartis Investigative Site Withdrawn
Pune, Maharashtra, India, 411 011
Novartis Investigative Site Active, not recruiting
Bikaner, Rajasthan, India, 334 001
Novartis Investigative Site Active, not recruiting
Jaipur, Rajasthan, India, 302023
Novartis Investigative Site Active, not recruiting
Jaipur, Rajasthan, India, 302 023
Novartis Investigative Site Withdrawn
Chennai, Tamil Nadu, India, 600 087
Novartis Investigative Site Active, not recruiting
Coimbatore, Tamil Nadu, India, 641 045.
Novartis Investigative Site Active, not recruiting
Vellore, Tamil Nadu, India, 632004
Novartis Investigative Site Withdrawn
Coimbatore, TN, India, 641037
Novartis Investigative Site Terminated
Ahmedabad, India, 380009
Novartis Investigative Site Withdrawn
Jaipur, India, 302017
Novartis Investigative Site Active, not recruiting
Nagpur - Maharashtra, India, 440012
Novartis Investigative Site Active, not recruiting
Panjim, India, 403002
Ireland
Novartis Investigative Site Withdrawn
Cork, Ireland
Novartis Investigative Site Withdrawn
Dublin 24, Ireland
Novartis Investigative Site Withdrawn
Dublin 9, Ireland
Novartis Investigative Site Withdrawn
Galway, Ireland
Israel
Novartis Investigative Site Withdrawn
Haifa, Israel, 34362
Novartis Investigative Site Active, not recruiting
Jerusalem, Israel, 91031
Novartis Investigative Site Active, not recruiting
Jerusalem, Israel, 91120
Novartis Investigative Site Active, not recruiting
Petach Tikva, Israel, 49100
Novartis Investigative Site Active, not recruiting
Rehovot, Israel, 76100
Korea, Republic of
Novartis Investigative Site Active, not recruiting
Bucheon-Si, Gyeonggi-Do, Korea, Republic of
Novartis Investigative Site Active, not recruiting
Seoul, Korea, Korea, Republic of, 110 744
Novartis Investigative Site Withdrawn
Seoul, Korea, Korea, Republic of, 135-710
Novartis Investigative Site Active, not recruiting
Daegu, Korea, Republic of, 705-717
Novartis Investigative Site Withdrawn
Daegu, Korea, Republic of, 700-712
Novartis Investigative Site Active, not recruiting
Incheon, Korea, Republic of, 403-010
Novartis Investigative Site Active, not recruiting
Incheon, Korea, Republic of
Novartis Investigative Site Active, not recruiting
Seoul, Korea, Republic of, 130-702
Novartis Investigative Site Active, not recruiting
Seoul, Korea, Republic of, 156-755
Novartis Investigative Site Active, not recruiting
Seoul, Korea, Republic of, 130-709
Latvia
Novartis Investigative Site Active, not recruiting
Daugavpils, Latvia, LV-5401
Novartis Investigative Site Active, not recruiting
Riga, Latvia, 1002
Novartis Investigative Site Active, not recruiting
Riga, Latvia, LV-1006
Lithuania
Novartis Investigative Site Withdrawn
Vilnius, LT, Lithuania, 01117
Novartis Investigative Site Withdrawn
Alytus, Lithuania, LT-62114
Novartis Investigative Site Withdrawn
Klaipeda, Lithuania, 92288
Novartis Investigative Site Withdrawn
Klaipeda, Lithuania, LT-92231
Novartis Investigative Site Withdrawn
Utena, Lithuania, LT-28151
Novartis Investigative Site Withdrawn
Vilnius, Lithuania, 06122
Novartis Investigative Site Withdrawn
Vilnius, Lithuania, LT-08661
Mexico
Novartis Investigative Site Active, not recruiting
Mexico, Distrito Federal, Mexico, 06726
Novartis Investigative Site Active, not recruiting
Mexico, Distrito Federal, Mexico, 14050
Novartis Investigative Site Withdrawn
México, Distrito Federal, Mexico, 14080
Novartis Investigative Site Active, not recruiting
León, Guanajuato, Mexico, 37000
Novartis Investigative Site Active, not recruiting
Pachuca, Hidalgo, Mexico, 42090
Panama
Novartis Investigative Site Active, not recruiting
Panama City, Panamá, Panama
Novartis Investigative Site Active, not recruiting
Panama City, Panamá, Panama, 0834-00363
Novartis Investigative Site Withdrawn
Panama City, Panamá, Panama
Poland
Novartis Investigative Site Active, not recruiting
Bialystok, Poland, 15-044
Novartis Investigative Site Active, not recruiting
Katowice, Poland, 40-752
Novartis Investigative Site Active, not recruiting
Krakow, Poland, 31-159
Novartis Investigative Site Active, not recruiting
Lodz, Poland, 90-302
Novartis Investigative Site Terminated
Lodz, Poland, 90-153
Russian Federation
Novartis Investigative Site Withdrawn
Moscow, Russian Federation, 121309
Novartis Investigative Site Active, not recruiting
Moscow, Russian Federation, 115280
Novartis Investigative Site Active, not recruiting
Moscow, Russian Federation, 125315
Novartis Investigative Site Withdrawn
Moscow, Russian Federation, 115446
Novartis Investigative Site Active, not recruiting
N.Novgorod, Russian Federation, 603126
Novartis Investigative Site Active, not recruiting
Nizhny Novgorod, Russian Federation, 603018
Novartis Investigative Site Active, not recruiting
Ryazan, Russian Federation, 390026
Novartis Investigative Site Withdrawn
Sankt-Peterburg, Russian Federation, 197022
Novartis Investigative Site Active, not recruiting
Saratov, Russian Federation, 410012
Novartis Investigative Site Active, not recruiting
St-Petersburg, Russian Federation, 193312
Novartis Investigative Site Completed
St. Petersburg, Russian Federation, 194354
Novartis Investigative Site Active, not recruiting
St.-Petersburg, Russian Federation, 193231
Novartis Investigative Site Active, not recruiting
Yaroslavl, Russian Federation, 150003
Serbia
Novartis Investigative Site Recruiting
Knez Selo, Serbia, 18204
Novartis Investigative Site Recruiting
Kragujevac, Serbia, 34000
Slovenia
Novartis Investigative Site Recruiting
Golnik, Slovenia, 4204
Turkey
Novartis Investigative Site Withdrawn
Istanbul, Turkey, 34854
Novartis Investigative Site Active, not recruiting
Kartal, Turkey, 34890
Novartis Investigative Site Active, not recruiting
Kocaeli, Turkey, 41380
Novartis Investigative Site Active, not recruiting
Mersin, Turkey, 33079
Novartis Investigative Site Active, not recruiting
Pendik / Istanbul, Turkey, 1330
Novartis Investigative Site Active, not recruiting
Yenisehir/Izmir, Turkey, 35110
United Kingdom
Novartis Investigative Site Withdrawn
East Sussex, Brighton, United Kingdom, BN41 1WE
Novartis Investigative Site Active, not recruiting
Leamington Spa, Warwickshire, United Kingdom, CV32 4RA
Novartis Investigative Site Active, not recruiting
Birmingham, United Kingdom, B9 5SS
Novartis Investigative Site Terminated
Birmingham, United Kingdom, B15 2WB
Novartis Investigative Site Active, not recruiting
Bradford, United Kingdom, BD9 6RJ
Novartis Investigative Site Active, not recruiting
Cheshire, United Kingdom, CW1 4QJ
Novartis Investigative Site Active, not recruiting
Doncaster, United Kingdom, DN2 5LT
Novartis Investigative Site Active, not recruiting
Leeds, United Kingdom, LS9 7TF
Novartis Investigative Site Active, not recruiting
Merseyside, United Kingdom, CH49 5PE
Novartis Investigative Site Active, not recruiting
Newport, United Kingdom, P030 5TG
Novartis Investigative Site Active, not recruiting
Portsmouth, United Kingdom, PO6 3AD
Novartis Investigative Site Active, not recruiting
Wolverhampton, United Kingdom, WV10 0QP
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01610037     History of Changes
Other Study ID Numbers: CQVA149A2339, 2012-002057-38
Study First Received: May 30, 2012
Last Updated: May 21, 2014
Health Authority: Argentina: Administracion Nacional de Alimentos, Medicamentos y Tecnologia Medica (ANMAT)
Croatia: Ministry of Health
Dominican Republic: Consejo Nacional de Bioetica en Salud (CONABIOS)
Estonia: State Agency of Medicine
Hungary: Directorate General of National Institute of Pharmacy/ National Institute for Quality and Organisational Development in Healthcare and Medicines
India: Drugs Controller General of India
Ireland: Irish Medicines Board (IMB)
Israel: Israeli Ministry of Health
South Korea: Korea Food and Drug Administration (KFDA)
Latvia: State Agency of Medicines of Latvia
Mexico: Ministry of Health
Panama: Comite Nacional de Bioetica de la Investigacion con sede en Instituto Conmemorativo Gorgas de Estudios de la Salud (Ministry of Health)
Poland: Ministry of Health
Russia: Ministry of Health of the Russian Federation
Serbia: Medicines and Medical Devices Agency of Serbia
Slovenia: Public Agency of the Republic of Slovenia for Medicinal Products and Medical Devices
Turkey: Ministry of Health - Turkish Medicines and Medical Devices Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Venezuela: Instituto Nacional de Higiene Rafael Rangel

Keywords provided by Novartis:
chronic obstructive pulmonary disease
COPD
QVA149
QAB149
NVA237
Indacaterol maleate
Glycopyronnium bromide

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases
Tiotropium
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 28, 2014